Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis, Abbott New R&D Models Focus On Translational Medicine

Executive Summary

Translational medicine will assist companies with targeting the right indication for a compound, a Novartis representative said at IBC's Drug Discovery Technology & Development conference Aug. 8 in Boston

You may also be interested in...

Novartis Proposes Two-Phase Drug Development Model, Staged Approval

Novartis is advocating a two-phase drug development paradigm based on "models of disease.

GMP Guidance For Phase I IND Trials Will Benefit Drug Manufacturers, Labs

Manufacturers and laboratories producing investigational new drugs in Phase I studies are exempt from having to fully validate their manufacturing process under new FDA guidelines

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts